JP2011518168A5 - - Google Patents

Info

Publication number

JP2011518168A5

JP2011518168A5 JP2011505126A JP2011505126A JP2011518168A5 JP 2011518168 A5 JP2011518168 A5 JP 2011518168A5 JP 2011505126 A JP2011505126 A JP 2011505126A JP 2011505126 A JP2011505126 A JP 2011505126A JP 2011518168 A5 JP2011518168 A5 JP 2011518168A5

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

compound

acceptable salt

therapeutic agent

item

Prior art date

2009-04-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 25
• 150000003839 salts Chemical class 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 17
• 229940124597 therapeutic agent Drugs 0.000 claims description 12
• 239000000203 mixture Substances 0.000 claims description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 7
• 201000010099 disease Diseases 0.000 claims description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 6
• YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims description 4
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 4
• 102000003996 Interferon-beta Human genes 0.000 claims description 4
• 108090000467 Interferon-beta Proteins 0.000 claims description 4
• 125000002723 alicyclic group Chemical group 0.000 claims description 4
• 125000001931 aliphatic group Chemical group 0.000 claims description 4
• 239000012472 biological sample Substances 0.000 claims description 4
• 125000001153 fluoro group Chemical group F* 0.000 claims description 4
• 229940042385 glatiramer Drugs 0.000 claims description 4
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
• 229960001156 mitoxantrone Drugs 0.000 claims description 4
• 229960005027 natalizumab Drugs 0.000 claims description 4
• 239000002552 dosage form Substances 0.000 claims description 3
• 239000008194 pharmaceutical composition Substances 0.000 claims description 3
• 208000023275 Autoimmune disease Diseases 0.000 claims description 2
• 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 claims description 2
• 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 claims description 2
• 239000002671 adjuvant Substances 0.000 claims description 2
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
• 210000004556 brain Anatomy 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims description 2
• 208000035475 disorder Diseases 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 125000000623 heterocyclic group Chemical group 0.000 claims description 2
• 239000001257 hydrogen Substances 0.000 claims description 2
• 229910052739 hydrogen Inorganic materials 0.000 claims description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
• 239000002955 immunomodulating agent Substances 0.000 claims description 2
• 229940121354 immunomodulator Drugs 0.000 claims description 2
• 230000002584 immunomodulator Effects 0.000 claims description 2
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
• 230000001861 immunosuppressant effect Effects 0.000 claims description 2
• 239000003018 immunosuppressive agent Substances 0.000 claims description 2
• 208000027866 inflammatory disease Diseases 0.000 claims description 2
• 230000002401 inhibitory effect Effects 0.000 claims description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
• 229910052757 nitrogen Inorganic materials 0.000 claims description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
• 210000000278 spinal cord Anatomy 0.000 claims description 2
• 239000003981 vehicle Substances 0.000 claims description 2
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 238000000034 method Methods 0.000 description 7
• 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1